Articles with "metastatic non" as a keyword



Association of Allostatic Load With Overall Mortality Among Patients With Metastatic Non–Small Cell Lung Cancer

Sign Up to like & get
recommendations!
Published in 2022 at "JAMA Network Open"

DOI: 10.1001/jamanetworkopen.2022.21626

Abstract: Key Points Question Is there an association among allostatic load (AL), social determinants of health (SDHs), and overall mortality in patients with metastatic non–small cell lung cancer (NSCLC)? Findings In this cross-sectional study of 143… read more here.

Keywords: non small; metastatic non; patients metastatic; overall mortality ... See more keywords

Trastuzumab Deruxtecan for ERBB2-Mutant Metastatic Non–Small Cell Lung Cancer With or Without Brain Metastases

Sign Up to like & get
recommendations!
Published in 2025 at "JAMA Network Open"

DOI: 10.1001/jamanetworkopen.2025.43107

Abstract: This secondary analysis evaluates systemic and intracranial effectiveness and safety of trastuzumab deruxtecan among participants in the DESTINY-Lung01 and DESTINY-Lung02 clinical trials. read more here.

Keywords: non small; mutant metastatic; erbb2 mutant; trastuzumab deruxtecan ... See more keywords

Real‐World Prevalence, Treatment Patterns, and Outcomes for Patients With HER2 (ERBB2)‐Mutant Metastatic Non‐Small Cell Lung Cancer, From a US‐Based Clinico‐Genomic Database

Sign Up to like & get
recommendations!
Published in 2024 at "Cancer Medicine"

DOI: 10.1002/cam4.70272

Abstract: Targeted therapies have been shown to improve outcomes in metastatic non‐small cell lung cancer (mNSCLC) with driver mutations. We evaluated the real‐world prevalence of human epidermal growth factor receptor 2 (HER2; ERBB2) tumor gene mutations… read more here.

Keywords: cancer; non small; lung cancer; cell lung ... See more keywords

Cumulative incidence and risk factors of brain metastases in metastatic non–small cell lung cancer without baseline brain metastasis: Pooled analysis of individualized patient data from IMpower130, IMpower131, and IMpower150

Sign Up to like & get
recommendations!
Published in 2024 at "Cancer"

DOI: 10.1002/cncr.35242

Abstract: The objective of this study was to explore the abilities of atezolizumab plus chemotherapy in preventing brain metastases (BMs) among metastatic non–small cell lung cancer (NSCLC) without initial BMs, as well as the risk factors… read more here.

Keywords: cancer; non small; brain; brain metastases ... See more keywords

Exceptional pemetrexed sensitivity can predict therapeutic benefit from subsequent chemotherapy in metastatic non-squamous non-small cell lung cancer

Sign Up to like & get
recommendations!
Published in 2019 at "Journal of Cancer Research and Clinical Oncology"

DOI: 10.1007/s00432-019-02941-z

Abstract: PurposeBased on an exceptionally durable response to pemetrexed observed in some patients with metastatic NSCLC, the predictive value of pemetrexed sensitivity to outcomes of subsequent systemic treatment was investigated.MethodsWe retrospectively reviewed the patients with metastatic… read more here.

Keywords: chemotherapy; metastatic non; non squamous; treatment ... See more keywords
Photo from wikipedia

Real-world outcomes of anti-PD1 antibodies in platinum-refractory, PD-L1-positive recurrent and/or metastatic non-small cell lung cancer, and its potential practical predictors: first report from Korean Cancer Study Group LU19-05

Sign Up to like & get
recommendations!
Published in 2021 at "Journal of Cancer Research and Clinical Oncology"

DOI: 10.1007/s00432-021-03527-4

Abstract: Although immune-checkpoint inhibitors have become a new therapeutic option for recurrent/metastatic non-small cell lung cancers (R/M-NSCLC), its clinical benefit in the real-world is still unclear. We investigated 1181 Korean patients with programmed death-1 ligand 1… read more here.

Keywords: recurrent metastatic; real world; metastatic non; group ... See more keywords

Immune Checkpoint Inhibition in Non-metastatic Non-small Cell Lung Cancer: Chance for Cure?

Sign Up to like & get
recommendations!
Published in 2019 at "Drugs"

DOI: 10.1007/s40265-019-01222-w

Abstract: Immune checkpoint inhibition of programmed-death receptor 1 (PD-1) or its ligand (PD-L1) has become a standard in the treatment of metastatic non-small cell lung cancer, either as monotherapy or in combination. Recently, it could be… read more here.

Keywords: immune checkpoint; metastatic non; cell lung; checkpoint inhibition ... See more keywords

Q-TWiST Analysis to Assess Benefit–Risk of Pembrolizumab in Patients with PD-L1–Positive Advanced or Metastatic Non-small Cell Lung Cancer

Sign Up to like & get
recommendations!
Published in 2018 at "Pharmacoeconomics"

DOI: 10.1007/s40273-018-0752-0

Abstract: ObjectivesPembrolizumab monotherapy showed significantly longer overall survival and fewer treatment-related adverse events compared to chemotherapy in patients with advanced or metastatic non-small cell lung cancer (NSCLC) with programmed death ligand-1 (PD-L1)–positive tumors in the first-line… read more here.

Keywords: advanced metastatic; non small; metastatic non; analysis ... See more keywords
Photo by priscilladupreez from unsplash

Outcomes of Patients With Metastatic Non–Clear‐Cell Renal Cell Carcinoma Treated With Pazopanib

Sign Up to like & get
recommendations!
Published in 2017 at "Clinical Genitourinary Cancer"

DOI: 10.1016/j.clgc.2016.07.016

Abstract: Micro‐Abstract Outcomes data in patients with metastatic non–clear‐cell renal cell carcinoma (RCC) treated with pazopanib are limited. We identified 29 patients with non–clear‐cell metastatic RCC who received pazopanib (9 in the front‐line setting, and 20… read more here.

Keywords: non clear; metastatic non; front line; cell ... See more keywords

Hypermetabolism is an independent prognostic factor of survival in metastatic non-small cell lung cancer patients.

Sign Up to like & get
recommendations!
Published in 2019 at "Clinical nutrition"

DOI: 10.1016/j.clnu.2019.08.003

Abstract: BACKGROUND & AIMS Metastatic non-small cell lung cancer (NSCLC) is the first cause of cancer death worldwide. Increased resting energy expenditure (REE) is frequent among cancer patients and may contribute to cancer cachexia. The aim… read more here.

Keywords: metastatic non; cell lung; independent prognostic; non small ... See more keywords
Photo from wikipedia

Metastatic non-Hematopoietic Neoplasms to the Breast: A Study of 238 Cases.

Sign Up to like & get
recommendations!
Published in 2022 at "Human pathology"

DOI: 10.1016/j.humpath.2022.04.009

Abstract: AIMS The aim of this study was to review the clinicopathologic characteristics of metastatic non-hematopoietic malignancies to the breast, in order to identify salient features for practicing pathologist that are useful in distinguishing metastatic lesions… read more here.

Keywords: metastatic non; 238 cases; non hematopoietic; study ... See more keywords